SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results

Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with

COCPOPK

Related stories